Iteos Therapeutics (ITOS) Earnings Preview: What to Expect from the Q2 2025 Report
With analysts forecasting a revenue decline and a significant per-share loss, all eyes are on the biotech firm's upcoming results and future guidance.
Cambridge, MA – Investors and market watchers are turning their attention to Iteos Therapeutics Inc. (NASDAQ: ITOS) as the clinical-stage biopharmaceutical company prepares to release its financial results for the second quarter ending June 30, 2025. The report, estimated to be released around August 6, is widely expected to show a year-over-year decline in quarterly revenue.
The key focus for stakeholders will be the company’s bottom line and its progress in its clinical development programs. Here’s a breakdown of what Wall Street is anticipating ahead of the announcement.
Analyst Estimates and Expectations
According to mean analyst estimates compiled by LSEG, Iteos Therapeutics is projected to post a loss of $1.01 per share for the quarter. This figure is a critical benchmark that investors will compare against the company’s actual reported earnings.
Notably, the consensus earnings estimate has remained stable over the last three months. This stability suggests that analysts have not significantly altered their outlook on the company’s near-term financial performance, indicating a consistent view of the challenges and milestones ahead. For a clinical-stage biotech firm, quarterly losses are common as significant capital is invested in research and development (R&D) long before products reach commercialization.
Current Wall Street Sentiment
The prevailing sentiment among financial analysts covering ITOS is one of caution and patience. The current average analyst rating on the shares is a “Hold.”
This neutral stance is unanimous among the five analysts providing recommendations:
Strong Buy/Buy: 0
Hold: 5
Sell/Strong Sell: 0
A “Hold” consensus indicates that analysts generally advise investors to maintain their existing positions rather than buying or selling the stock at its current valuation, likely pending new clinical data or strategic updates from the company.
Price Target and Valuation
Wall Street’s median 12-month price target for Iteos Therapeutics stands at $10.27 per share. Based on the stock’s last closing price of $10.09, this target represents a modest upside of approximately 1.8%. This limited potential upside aligns with the “Hold” rating, suggesting that analysts do not foresee significant price movement in the near future without a major positive catalyst.
Looking Back: Previous Performance
To contextualize the upcoming report, investors will compare the Q2 2025 results against the company’s recent performance. Examining how Iteos has performed relative to past Wall Street estimates can provide insight into management’s ability to meet, exceed, or fall short of expectations.
(Note: The table below is a template for tracking historical performance.)
| Period Ending | Reported EPS (USD) | Consensus EPS Estimate (USD) | Surprise (%) |
| Mar 31, 2025 | (Data) | (Data) | (Data) |
| Dec 31, 2024 | (Data) | (Data) | (Data) |
| Sep 30, 2024 | (Data) | (Data) | (Data) |
| Jun 30, 2024 | (Data) | (Data) | (Data) |
When Iteos reports its results, investors will be keen to see not only the headline revenue and EPS figures but also listen for any forward-looking guidance provided by management during the subsequent conference call. Updates on clinical trial progress, cash burn rate, and potential partnerships will be crucial in shaping the stock’s direction.
